Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years
- PMID: 25268439
- DOI: 10.1001/jama.2014.12679
Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years
Abstract
Importance: The choice between bioprosthetic and mechanical aortic valve replacement in younger patients is controversial because long-term survival and major morbidity are poorly characterized.
Objective: To quantify survival and major morbidity in patients aged 50 to 69 years undergoing aortic valve replacement.
Design, setting, and participants: Retrospective cohort analysis of 4253 patients aged 50 to 69 years who underwent primary isolated aortic valve replacement using bioprosthetic vs mechanical valves in New York State from 1997 through 2004, identified using the Statewide Planning and Research Cooperative System. Median follow-up time was 10.8 years (range, 0 to 16.9 years); the last follow-up date for mortality was November 30, 2013. Propensity matching yielded 1001 patient pairs.
Main outcomes and measures: Primary outcome was all-cause mortality; secondary outcomes were stroke, reoperation, and major bleeding.
Results: No differences in survival or stroke rates were observed in patients with bioprosthetic compared with mechanical valves. Actuarial 15-year survival was 60.6% (95% CI, 56.3%-64.9%) in the bioprosthesis group compared with 62.1% (95% CI, 58.2%-66.0%) in the mechanical prosthesis group (hazard ratio, 0.97 [95% CI, 0.83-1.14]). The 15-year cumulative incidence of stroke was 7.7% (95% CI, 5.7%-9.7%) in the bioprosthesis group and 8.6% (95% CI, 6.2%-11.0%) in the mechanical prosthesis group (hazard ratio, 1.04 [95% CI, 0.75-1.43). The 15-year cumulative incidence of reoperation was higher in the bioprosthesis group (12.1% [95% CI, 8.8%-15.4%] vs 6.9% [95% CI, 4.2%-9.6%]; hazard ratio, 0.52 [95% CI, 0.36-0.75]). The 15-year cumulative incidence of major bleeding was higher in the mechanical prosthesis group (13.0% [95% CI, 9.9%-16.1%] vs 6.6% [95% CI, 4.8%-8.4%]; hazard ratio, 1.75 [95% CI, 1.27-2.43]). The 30-day mortality rate was 18.7% after stroke, 9.0% after reoperation, and 13.2% after major bleeding.
Conclusions and relevance: Among propensity-matched patients aged 50 to 69 years who underwent aortic valve replacement with bioprosthetic compared with mechanical valves, there was no significant difference in 15-year survival or stroke. Patients in the bioprosthetic valve group had a greater likelihood of reoperation but a lower likelihood of major bleeding. These findings suggest that bioprosthetic valves may be a reasonable choice in patients aged 50 to 69 years.
Comment in
-
Age cutoffs for bioprosthetic vs mechanical aortic valve replacement.JAMA. 2015 Feb 3;313(5):522-3. doi: 10.1001/jama.2014.17228. JAMA. 2015. PMID: 25647211 No abstract available.
-
Age cutoffs for bioprosthetic vs mechanical aortic valve replacement--reply.JAMA. 2015 Feb 3;313(5):523-4. doi: 10.1001/jama.2014.17231. JAMA. 2015. PMID: 25647212 No abstract available.
Similar articles
-
Survival and outcomes following bioprosthetic vs mechanical mitral valve replacement in patients aged 50 to 69 years.JAMA. 2015 Apr 14;313(14):1435-42. doi: 10.1001/jama.2015.3164. JAMA. 2015. PMID: 25871669
-
Bioprosthetic aortic valve replacement: Revisiting prosthesis choice in patients younger than 50 years old.J Thorac Cardiovasc Surg. 2018 Feb;155(2):539-547.e9. doi: 10.1016/j.jtcvs.2017.08.121. Epub 2017 Sep 13. J Thorac Cardiovasc Surg. 2018. PMID: 29110948
-
Late outcomes comparison of nonelderly patients with stented bioprosthetic and mechanical valves in the aortic position: a propensity-matched analysis.J Thorac Cardiovasc Surg. 2014 Nov;148(5):1931-9. doi: 10.1016/j.jtcvs.2013.12.042. Epub 2014 Jan 15. J Thorac Cardiovasc Surg. 2014. PMID: 24521965
-
What is the best approach in a patient with a failed aortic bioprosthetic valve: transcatheter aortic valve replacement or redo aortic valve replacement?Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):837-43. doi: 10.1093/icvts/ivv037. Epub 2015 Mar 8. Interact Cardiovasc Thorac Surg. 2015. PMID: 25754372 Review.
-
Mechanical versus bioprosthetic aortic valve replacement.Eur Heart J. 2017 Jul 21;38(28):2183-2191. doi: 10.1093/eurheartj/ehx141. Eur Heart J. 2017. PMID: 28444168 Review.
Cited by
-
Medium-term survival of patients with mechanical and biological aortic prosthesis at the 6th decade of life.PLoS One. 2024 Nov 18;19(11):e0312408. doi: 10.1371/journal.pone.0312408. eCollection 2024. PLoS One. 2024. PMID: 39556548 Free PMC article.
-
Biological Surgical Options in Young Patients for the Treatment of Severe Aortic Stenosis: Is the Jury Still Out? A Review.Rev Cardiovasc Med. 2022 Jul 26;23(8):274. doi: 10.31083/j.rcm2308274. eCollection 2022 Aug. Rev Cardiovasc Med. 2022. PMID: 39076635 Free PMC article. Review.
-
Long-Term Outcomes of Bioprosthetic and Mechanical Valve Replacement for Patients Aged between 50 and 70 Years.Rev Cardiovasc Med. 2023 Sep 18;24(9):253. doi: 10.31083/j.rcm2409253. eCollection 2023 Sep. Rev Cardiovasc Med. 2023. PMID: 39076400 Free PMC article.
-
2023 Korean Society of Echocardiography position paper for diagnosis and management of valvular heart disease, part I: aortic valve disease.J Cardiovasc Imaging. 2024 Jul 26;32(1):11. doi: 10.1186/s44348-024-00019-0. J Cardiovasc Imaging. 2024. PMID: 39061115 Free PMC article. Review.
-
Age-Specific Outcomes of Bioprosthetic vs. Mechanical Aortic Valve Replacement: Balancing Reoperation Risk with Anticoagulation Burden.J Cardiovasc Dev Dis. 2024 Jul 18;11(7):227. doi: 10.3390/jcdd11070227. J Cardiovasc Dev Dis. 2024. PMID: 39057647 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
